Mercy BioAnalytics adds two new executive positions in push toward commercialization
PHOTO | Courtesy of Google Maps
ABI Lab in Natick is home to Mercy BioAnalytics, among other biotech firms.
Natick-based cancer detection firm Mercy BioAnalytics has added two executive positions to its roster ahead of commercialization plans for its product.
The firm secured $41 million in May in its series A financing round, to be used for commercialization of the company’s primary technology, the Mercy Halo test, which uses liquid biopsies in pursuit of the early detection of cancer.
Josh Gralapp has joined Mercy as vice president for marketing and strategic alliances, and Tim Membrino has joined as vice president for program and portfolio Management, according to a Monday press release from Mercy BioAnalytics. Both positions are new at the firm ahead of commercialization.
Gralapp was previously responsible for developing product commercialization strategy as vice president of commercial for Delfi Diagnostics in Baltimore. He holds an MBA from Santa Clara University and a bachelor’s degree in chemistry from California State University, Chico.
Membrino led product development and operations at Quanterix Corporation in Billerica as vice president for program and portfolio management. He holds a bachelor’s degree from Worcester Polytechnic Institute and a master’s degree from Embry-Riddle Aeronautical University.
“We continue to make rapid progress in the development of our screening tests for those at high risk of developing lung and ovarian cancer,” said Mercy CEO Dawn Mattoon in the press release. “Josh and Tim are exceptional leaders who share a passion for our mission to save lives and relieve suffering globally through the early detection of cancer. Their skills and experience will be instrumental as we execute our commercialization roadmap and look to expand and diversify our product pipeline.”
The firm is working to solidify its position in the Central Mass. life science economy as it ages out of the startup phase.
WBJ Web Partners
Most Recent
Most Recent
0 Comments